.INVESTIGATION FEATURE.06 August 2024.
A sizable randomized measured trial with cisgender women highlights the problems of fidelity to a regular oral preexposure treatment regiment and also demonstrates that twice-yearly shot of lenacapavir can preserve helpful HIV deterrence levels over 6 months.